Biomed Central Ltd

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Autio
    Autio
  4. Rosenberg
    Rosenberg
  5. Shah
    Shah
  6. Carlo
    Carlo
  7. Kotecha
    Kotecha
  8. Solit
    Solit
  9. Feldman
    Feldman
  10. Iyer
    Iyer

Groups

  1. Department of Medicine (81)
  2. Genitourinary Oncology Service (81)
  3. Solid Tumor Oncology Division (81)
  4. Weinberg Fellows (14)
  5. GSK Faculty (13)
  6. Hematologic Malignancies, Division of (12)
  7. Human Oncology and Pathogenesis Program (10)
  8. Epidemiology and Biostatistics (9)
  9. Biostatistics Service (7)
  10. Survivorship Research (7)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (51)
  2. Meeting Abstract (27)
  3. Guidelines (2)
  4. Review (1)
Groups
  1. Department of Medicine (81)
  2. Genitourinary Oncology Service (81)
  3. Solid Tumor Oncology Division (81)
  4. Weinberg Fellows (14)
  5. GSK Faculty (13)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Robert Motzer (22)
  2. Martin Voss (15)
  3. Karen Autio (11)
  4. Jonathan Rosenberg (8)
  5. Neil Shah (7)
  6. Chung-Han Lee (5)

More People

Years
  1. 2024 (2)
  2. 2023 (5)
  3. 2022 (13)
  4. 2021 (14)
  5. 2020 (7)
  6. 2019 (4)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (53)
  2. BMC Cancer (8)
  3. Genome Medicine (4)
  4. Journal of Hematology & Oncology (3)
  5. Journal of Translational Medicine (3)
  6. Breast Cancer Research (2)

More Publications

Results (81)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
    Journal Article

    Grivas, P.; Loriot, Y.; Morales-Barrera, R.; Teo, M. Y.; Zakharia, Y.; Feyerabend, S.; Vogelzang, N. J.; Grande, E.; Adra, N.; Alva, A.; more...
    BMC Cancer (2021)

    Fulltext@MSK | Save
  • Considerations for treatment duration in responders to immune checkpoint inhibitors
    Review

    Marron, T. U.; Ryan, A. E.; Reddy, S. M.; Kaczanowska, S.; Younis, R. H.; Thakkar, D.; Zhang, J.; Bartkowiak, T.; Howard, R.; Anderson, K. G.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Imaging features of fumarate hydratase-deficient renal cell carcinomas: A retrospective study
    Journal Article

    Nikolovski, I.; Carlo, M. I.; Chen, Y. B.; Vargas, H. A.
    Cancer Imaging (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 3 study (Cosmic-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
    Meeting Abstract

    Choueiri, T.; Albiges, L.; Powles, T.; Mohamed, N.; Wang, F.; Motzer, R.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Dorff, T.; Rettig, M.; Machiels, J. P.; Lolkema, M.; Autio, K.; Greil, R.; Rottey, S.; Adra, N.; Salvati, M.; Poon, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
    Meeting Abstract

    Zappasodi, R.; Serganova, I.; Cohen, I.; Maeda, M.; Senbabaoglu, Y.; Shindo, M.; Maniyar, R.; Mane, M.; Leftin, A.; Watson, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Journal Article

    Garrido-Castro, A. C.; Saura, C.; Barroso-Sousa, R.; Guo, H.; Ciruelos, E.; Bermejo, B.; Gavilá, J.; Serra, V.; Prat, A.; Paré, L.; more...
    Breast Cancer Research (2020)

    Fulltext@MSK | Save
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
    Journal Article

    Motzer, R. J.; Escudier, B.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Powles, T.; Donskov, F.; Plimack, E. R.; Barthélémy, P.; Hammers, H. J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save